Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 88.80M -80.3% |
| Revenue (ttm) | n/a |
| Net Income | -212.75M |
| EPS | -1.22 |
| Shares Out | 187.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 356,870 |
| Open | 0.5699 |
| Previous Close | 0.4870 |
| Day's Range | 0.4726 - 0.5699 |
| 52-Week Range | 0.3154 - 3.6500 |
| Beta | 3.14 |
| Analysts | Buy |
| Price Target | 6.00 (+1,169.57%) |
| Est. Earnings | Nov 17, 2026 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 1,169.57% from the latest price.
News
Neumora Therapeutics price target lowered to $3 from $4 at Mizuho
Mizuho lowered the firm’s price target on Neumora Therapeutics (NMRA) to $3 from $4 and keeps an Outperform rating on the shares.
Neumora CEO transition not a surprise, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao views the appointment of Josh Pinto as Neumora Therapeutics’s (NMRA) next CEO as a “natural transition.” The CEO transition is not a surprise as the…
Neumora Therapeutics reports Q2 EPS (23c), consensus (24c)
“We delivered another quarter of disciplined execution against our strategic priorities, advancing key programs across our pipeline and positioning Neumora for a series of meaningful clinical mileston...
Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed
Neumora announced the appointment of Joshua Pinto as president and chief executive officer and a member of the board. Co-founder Paul Berns, will serve as executive chair. Additionally, Neumora appoin...
Neumora Therapeutics Slides: Company presentation
Neumora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026
Neumora Therapeutics Earnings release: Q2 2026
Neumora Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Neumora Therapeutics Quarterly report: Q2 2026
Neumora Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study
Neumora Therapeutics (NMRA) reported pre-clinical toxicology results from NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity and cardiometabolic disea...
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study...
Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Neumora Therapeutics (NMRA) to $5 from $7 and keeps an Outperform rating on the shares. The company’s later-stage neuro…
Neumora Therapeutics Slides: Corporate presentation
Neumora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Neumora Therapeutics price target lowered to $4 from $6 at Mizuho
Mizuho lowered the firm’s price target on Neumora Therapeutics (NMRA) to $4 from $6 and keeps an Outperform rating on the shares following the negative Phase 3 KOASTAL-2 and -3…
Neumora Therapeutics Slides: Investor presentation
Neumora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Neumora Therapeutics price target lowered to $5 from $8 at Needham
Needham analyst Ami Fadia lowered the firm’s price target on Neumora Therapeutics (NMRA) to $5 from $8 and keeps a Buy rating on the shares. The company will be discontinuing…
Neumora Therapeutics price target lowered to $7 from $18 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $18 and keeps a Buy rating on the shares after the company announced that the Phase…
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
Clear Street analyst Kaveri Pohlman keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX). The firm contends that Neumora Therapeutics (NMRA) Phase 3 KOASTAL failure has…
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
Neumora Therapeutics (NMRA) announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder did not achieve statistical significance on the primary or...
Neumora Therapeutics scraps depression drug after two late-stage trial failures
Neumora Therapeutics said on Monday it would stop developing its depression drug after two late-stage trials failed to meet their main goals.
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease a...
Neumora Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, re-elected Class III directors, ratified Ernst & Young as auditor, and approved executive compensation and annual advisory votes. Final results will be filed with the SEC.
Neumora Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Navacaprant phase III studies were optimized for patient selection and will report data this quarter, with NDA strategy possibly using pooled and safety data. NMRA-511 shows efficacy in Alzheimer's agitation; more studies are planned. NMRA-215 shows semaglutide-like weight loss preclinically, and NMRA-898 advances with strong CNS properties and upcoming data.
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
“We focused on steady execution during the first quarter, highlighted by the full enrollment of the navacaprant KOASTAL-2 and -3 studies with more than 400 patients per study. We look…
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and ...